Introduction

Intraductal papillary mucinous neoplasm (IPMN) is a pancreatic exocrine tumour characterised by cystic dilatation of the main and/or branch pancreatic ducts; these ducts are lined with a mucin-producing atypical epithelium that often proliferates in a papillary fashion [1–3]. IPMN is associated with a spectrum of diseases ranging from adenoma to invasive pancreatic ductal adenocarcinoma (PDAC). PDAC may be derived from IPMN or may concomitantly develop in other regions of a pancreas in which IPMN has developed. The two IPMN-related forms of PDAC are considered to be different disease entities due to their different proximities to the IPMN in the pancreas. However, the prognosis of these IPMN-related forms of PDAC is often better than that of ordinary PDAC if early diagnosis is made [4,5]. In contrast, the genetic characteristics of these two IPMN-related forms of PDAC and the reasons for their differing prognoses are not fully understood.

PDAC arises as a result of the accumulation of genetic and epigenetic mutations that confer a selective advantage to cancer cells [6,7]. Mutations in KRAS, CDKN2A, TP53, and SMAD4 have been frequently reported in cases of PDAC using conventional methods such as direct sequencing [8]. Recently, whole-exome analysis using next-generation sequencing has also revealed high-frequency alterations in these few genes [6,7,9].

In contrast, somatic oncogenic mutations in the guanine nucleotide binding protein, alpha stimulating (GNAS)-encoding G

Deep Sequencing of Cancer-Related Genes Revealed GNAS Mutations to Be Associated with Intraductal Papillary Mucinous Neoplasms and Its Main Pancreatic Duct Dilation

Shinichi Takano*, Mitsuharu Fukasawa, Shinya Maekawa, Makoto Kadokura, Mika Miura, Hiroko Shindo, Ei Takahashi, Tadashi Sato, Nobuyuki Enomoto

First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan

Abstract

Background: To clarify the genetic mutations associated with intraductal papillary mucinous neoplasms (IPMN) and IPMN-related pancreatic tumours, we conducted cancer-related gene profiling analyses using pure pancreatic juice and resected pancreatic tissues.

Methods: Pure pancreatic juice was collected from 152 patients [nine with a normal pancreas, 22 with chronic pancreatitis (CP), 39 with pancreatic ductal adenocarcinoma (PDAC), and 82 with IPMN], and resected tissues from the pancreas were collected from 48 patients (six IPMNs and 42 PDACs). The extracted DNA was amplified by multiplexed polymerase chain reaction (PCR) targeting 46 cancer-related genes containing 739 mutational hotspots. The mutations were analysed using a semiconductor-based DNA sequencer.

Results: Among the 46 cancer-related genes, KRAS and GNAS mutations were most frequently detected in both PDAC and IPMN cases. In pure pancreatic juice, GNAS mutations were detected in 7.7% of PDAC cases and 41.5% of IPMN cases (p = 0.001 vs. others). All PDAC cases with GNAS mutations were accompanied by dilated main pancreatic ducts (MPD, p = 0.016), while no statistically independent associations with clinical variables were observed for KRAS mutations. In the resected pancreatic tissues, GNAS mutations were detected in 50% of PDAC cases concomitant with IPMN, 33.3% of PDAC cases derived from IPMN, and 66.7% of IPMN cases, while no GNAS mutations were detected in cases of PDAC without IPMN.

Conclusions: The GNAS mutation was specifically found in the cases with IPMN and it was speculated that some PDACs might be influenced by the concomitant but separately-located IPMN in their pathogenic mechanism. Furthermore, the GNAS mutation was significantly associated with MPD dilatation in IPMN cases, suggesting its role in mucus hypersecretion.
protein, have been recently identified in 41–66% of IPMN cases [10–12]. GNAS mutations have also been identified in several tumours of the endocrine system [13], some pituitary adenomas [14], and in McCune–Albright syndrome [15]. These mutations arise very early in the natural development of IPMN [10] and are highly specific to IPMN [11,12,16]. With the exception of a small percentage of pancreatic intra-epithelial neoplasias (PanINs), GNAS mutations have seldom been detected in most cases of PDAC or other cystic neoplasms [11,12,16]. However, it is unknown how the clinical presentation of IPMN may be influenced by GNAS mutation. Moreover, it is also unknown whether IPMN-related PDACs are associated with GNAS mutations.

The detection of these mutations in pancreatic juice [17–21] or in samples obtained by endoscopic ultrasound fine-needle aspiration (EUS-FNA) [22] aids in the diagnosis of early-stage disease. However, only a few commonly mutated genes may be analysed in small samples due to the limitations in conventional sequencing technology. To alleviate these limitations, semiconductor-based next-generation sequencing has recently been developed and enabled rapid, deep, and cost-effective sequencing of a wide range of DNA from small clinically-obtained samples [23].

In this study, semiconductor-based sequencing was employed to conduct cancer-related gene mutation analysis for pancreatic neoplasms using small tissue samples. Using pure pancreatic juice, we investigated the mutational profiling of the pancreatic neoplasms and the association of this profile with the clinical variables.

In addition, using resected tissues, we compared the differences in the mutational profiling of the two types of PDACs that were related to IPMN (PDAC derived from IPMN and PDAC concomitant with IPMN).

Materials and Methods

Patients and samples

The pure pancreatic juices and associated clinical information were obtained from 152 cases (IP (chronic pancreatitis), n = 22; PDAC, n = 39; IPMN, n = 82; normal pancreas, n = 9) that were treated at Yamanashi University Hospital from 2000 to 2012 (Table 1). Thorough pancreatic examinations were performed in all cases. Endoscopic nasopancreatic drainage (ENPD) was performed during endoscopic retrograde cholangiopancreatography (ERCP) to obtain the pancreatic juice for cytological testing. The pure pancreatic juice was obtained and immediately stored at −80°C until use. In cases with biliary disease and a normal pancreas, the ENPD was performed to avoid post-ERCP pancreatitis, and the collected pancreatic juices were classified as normal pancreatic cases in the analysis. Resected tissues were obtained at the same hospital from 2006 to 2012 from cases with IPMN (n = 6) and PDAC (n = 42), as shown in Table 2. Of the PDAC tissue specimens, 21 were macrodissected frozen specimens and 21 were microdissected formalin-fixed paraffin-embedded (FFPE) specimens, whereas six of the IPMN samples were frozen specimens. The diagnosis and classification of IPMN were based on the international consensus guidelines for the management of IPMN and mucinous cystic neoplasms of the pancreas that were established in 2006 [1]. This study was approved by the Human Ethics Review Committee of Yamanashi University Hospital. Written informed consent was obtained from all patients.

DNA extraction

DNA from the resected tissues was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) for the frozen specimens and QIAamp DNA FFPE Kit (Qiagen) for the FFPE specimens. DNA from the pure pancreatic juice was extracted using the DNeasy Blood Mini Kit (Qiagen) as per the manufacturer’s instructions. On average, 1.4 μg and 0.3 μg of DNA were extracted from the frozen specimens and FFPE specimens, respectively, and approximately 3–4 μg of DNA were extracted from 400 μL of pure pancreatic juice.

Preparation of amplicon libraries

The Ion AmpliSeq Cancer Panel (Life Technologies, Carlsbad, CA, USA) was used to generate target amplicon libraries, as described previously [23]. In brief, 10 ng of DNA was amplified by PCR using pre-mixed Ion AmpliSeq Cancer Primer Pools containing 190 primer pairs and the AmpliSeq HiFi Master Mix (Ion AmpliSeq Library Kit, Life Technologies). The 190 multiplexed amplicons were treated with FuPa Reagent (Life Technologies) for partial digestion of the primer sequences and phosphorylation. The amplicons were then ligated to adapters from the Ion Xpress Barcode Adapters 1–16 Kit (Life Technologies) according to the manufacturer’s instructions. After ligation, the amplicons underwent nick-translation and additional library amplification by PCR to complete the linkage between the adapters and amplicons. The BioAnalyzer High Sensitivity DNA Kit (Agilent, Santa Clara, CA, USA) was used to visualise the size and range and to determine the library concentrations.

Emulsion PCR and sequencing

Multiplexed barcoded libraries were amplified by emulsion PCR on Ion Sphere particles (ISPs) using the Ion One Touch 200 Template Kit v2 (Life Technologies) as per the manufacturer’s instructions. After the template ISPs were recovered from the emulsion, the positive template ISPs were biotinylated during the emulsion process and enriched with Dynabeads MyOne Streptavidin C1 beads (Life Technologies). Sequencing was performed on a Personal Genome Machine Sequencer (Life Technologies) using the Ion PGM 200 Sequencing Kit (Life Technologies) according to the manufacturer’s instructions. Since the DNA-mutated tumour cells might exist as minor populations in the samples because of the small proportions among the whole tumour tissues and/or the contamination with non-tumour cells, deep sequencing analysis was conducted in this study to detect mutations at a rate as low as 1%. Torrent Suite v2.2 software (Life Technologies) was used to parse the barcoded reads, to align reads to the reference genome, and to run metrics, including chip-loading efficiency and total read counts and quality. Variants were identified with Variant Caller v2.0 software (Life Technologies). The quality value of the targeted base was set at 21, which is equal to 0.79% of the probability for error in mutation detection. The threshold of the mutation detection ratio was set at ≥1%. The Ion AmpliSeq Cancer Panel (Life Technologies), which was used in library amplification, targets 739 mutation sites of 46 cancer-related genes that were reported in the Catalogue of Somatic Mutations in Cancer (COSMIC; hotspot mutations) [24]; these detected hotspot mutations were analysed in combination with the clinical variables. The 46 cancer-related genes are listed on the horizontal axis of the graph in Figure 1 and Figure 2.

Statistical analysis

The associations between the gene mutations and clinical variables were evaluated using Fisher’s exact test or the χ² test and variables with a p value<0.2 were included in the multivariate analysis. Continuous data such as cyst size and presence of mural nodules were categorized according to receiver operating characteristic (ROC) analysis (data not shown). For the multivariate
analysis, a multiple logistic regression model was used, and a p-value < 0.05 was considered to be significant.

Results

Deep sequence analysis of 46 cancer-related genes in pure pancreatic juice

The cancer-related mutations in the 46 genes were analysed in the pure pancreatic juice of the 152 cases, with an average of 2,114 reads per amplicon. The extracted variants with the list of altered genes, variant frequency, read depth, and corresponding COSMIC IDs from the deep-sequencing data of each case have been attached as supporting information to this paper as Microsoft Excel-formatted files (File S1–S4). No mutation was detected in the pancreatic juice of the nine cases with normal pancreatic tissue (Fig. 1A). A GNAS mutation was detected in one case with CP that was accompanied by a small cyst (5 mm); this may have been representative of an early IPMN lesion (Fig. 1B and Fig. 3A). KRAS, GNAS, and TP53 mutations were detected in both PDAC and IPMN cases (Fig. 1).

KRAS mutations were detected in 20.5% of PDAC cases ($p = 0.0074$ vs. normal and CP) and 39.0% of IPMN cases ($p < 0.001$ vs. normal and CP). GNAS mutations were detected in 7.7% of PDAC cases and 41.5% of IPMN cases ($p < 0.001$ vs. others). IPMN was present in all PDAC cases that contained the GNAS mutation (n = 3).

Since our analysis demonstrated that the GNAS mutation was specific to IPMN, the associations between the selected clinical variables and GNAS status in the 82 IPMN cases were statistically analysed to clarify the clinical relevance and importance of the GNAS mutation in the pancreatic juice. The univariate analysis revealed an association between the GNAS mutation and the IPMN type (main duct type) and amount of dilatation ($\geq 6$ mm) in the MPD (Table 3). In the multivariate analysis, only MPD dilatation was independently associated with GNAS mutation (Table 3). On the other hand, the KRAS mutation was associated with the location (pancreas body and tail, $p = 0.044$) and amount of dilatation ($\geq 6$ mm) in the MPD ($p = 0.01$) by the univariate analysis; however, there was no independent clinical association with this mutation after the multivariate analysis (data not shown).

Table 1. Characteristics of the cases from whom the pancreatic juice was obtained.

| Variable                  | Pancreatic juice (n = 152) |
|---------------------------|-----------------------------|
|                           | Normal (n = 9) | CP (n = 22) | PDAC (n = 39) | IPMN (n = 82) |
| Age (Median (Range))      | 74 (48–85)     | 57 (35–79)  | 71 (49–82)   | 72 (37–85)    |
| Sex M/F                   | 4/5            | 11/11       | 24/15        | 47/35         |
| Location Head/Body and tail | 23/16        | 42/40       |
| Size (mm) Median (Range)  | 22 (3–70)      |
| UICC Stage 0–II/III–IV    | 20/19          |
| No. of concomitant IPMN   | 8              |
| Grade of IPMN Noninvasive/Invasive | 65/17 |
| IPMN type Main duct/Branch | 33/49         |
| Cyst size (mm) Median (Range) | 35 (5–139)  |
| MPD (mm) Median (Range)   | 4.5 (0.5–28)   |

CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct.

doi:10.1371/journal.pone.0098718.t001

Table 2. Characteristics of the cases from whom the pancreatic resected tissues were obtained.

| Variable                  | Pancreatic tissues (n = 48) |
|---------------------------|-----------------------------|
|                           | PDAC (n = 42) | concomitant with IPMN | derived from IPMN | IPMN (n = 6) | without PDAC |
|                           | without IPMN | with IPMN | IPMN | without PDAC |
| Age (Median (Range))      | 67.5 (51–80) | 75.5 (63–82) | 75.5 (37–80) | 72.5 (62–81) |
| Sex M/F                   | 14/12         | 6/4        | 4/2  | 5/1          |
| Location Head/Body and tail | 15/11   | 8/2        | 1/5  | 2/4          |
| Size (mm) Median (Range)  | 23 (13–42)   | 21 (18–35) | 42.5 (15–65) |
| UICC Stage 0–II/III–IV    | 17/9          | 5/5        | 5/1  |
| IPMN type Main duct/Branch | 0/10          | 5/1        | 5/1  |
| Cyst size (mm) Median (Range) | 0.2 (0.1–0.5) |
| MPD (mm) Median (Range)   | 4.45 (1.2–8)  |

PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct.

doi:10.1371/journal.pone.0098718.t002
Deep sequence analysis of 46 cancer-related genes in resected pancreatic tumour tissues

After we found the GNAS mutation in cases that had PDAC concomitant with IPMN as well as in cases that had only IPMN from the analysis of the pancreatic juice, we next sequenced tissue samples to determine the possible mutational patterns in IPMN, PDAC derived from IPMN, PDAC that was concomitant with IPMN, and PDAC alone. The sequencing was performed in 48 resected pancreatic tumours (PDAC without IPMN, n = 26; PDAC concomitant with IPMN, n = 10; PDAC derived from IPMN, n = 6; noninvasive IPMN, n = 6; Fig. 2). The average number of reads per amplicon was 2,582. The extracted variants with the list of altered genes, variant frequency, read depth, and corresponding COSMIC ID from the deep-sequencing data of each case have been attached to this paper as supporting information in Microsoft Excel-formatted files (File S5–S8).

KRAS mutations were detected in 84.6% of PDAC cases without IPMN, 80% of PDAC cases that were concomitant with IPMN, 66.7% of PDAC cases that were derived from IPMN, and 100% of IPMN cases. GNAS mutations were detected in 50% of PDAC cases that were concomitant with IPMN (p = 0.0007 vs. PDAC without IPMN), 33.3% of PDAC cases that were derived from IPMN (p = 0.03 vs. PDAC without IPMN), and 66.7% of IPMN cases (p = 0.0004 vs. PDAC without IPMN), while no GNAS mutations were detected in cases of PDAC without IPMN. GNAS mutations were thus only detected in IPMN and IPMN-associated PDAC (PDAC concomitant with IPMN and PDAC derived from IPMN). A detailed list of gene mutations is provided in Table 4. Thus, similar characteristics in gene mutations were observed for these three disease categories (Table 4).

Radiological images of PDAC concomitant with IPMN
The radiological images for cases 28, 30, and 31 in Table 4 are shown in Figure 3 as representative images that demonstrated PDAC concomitant with IPMN. In these cases, the GNAS mutations were detected in PDAC and the concomitant IPMN was located in a separate pancreatic region. For example, pancreatic duct strictures as a result of PDAC were evident in the pancreatic head in case 30 (Fig. 3B) and case 31 (Fig. 3C), while the IPMN was visible in the pancreatic body. In case 28...
(Fig. 3D), a low-density mass lesion of PDAC and the multiple cystic lesions of IPMN were apparently separated in the pancreas.

**Association of mutational patterns between pancreatic juice and resected pancreatic tumour tissues**

Some genes such as **ATM**, **BRAF**, **IDH1**, and **RB1** were detected only in the pancreatic juice (Fig. 1) but not in the resected tissues (Fig. 2). In contrast, the percentage of cases with mutations of **KRAS** or **GNAS** was higher in the resected tissues than in the pancreatic juice (Fig. 1, 2). In order to investigate if the mutational profiles of the pancreatic juice properly represented those of the pancreatic tumours, the mutational profiles between the pancreatic juice and resected pancreatic tumour tissues were compared in 21 cases for which both samples were available. Among the **KRAS** (n = 17) and **GNAS** (n = 7) mutations found in the 21 resected pancreatic tumour tissues, the **KRAS** and **GNAS** mutations were detected in the pancreatic juice in 41.2% (7/17) and 71.4% (5/7) of cases, respectively (Table 5), indicating that the sensitivity of pancreatic juice for the detection of mutations of pancreatic tumours may reach approximately 50%. If we look at the specifics among the **KRAS** (n = 11) and **GNAS** (n = 4) mutations found in the resected pancreatic tissues of the 15 PDAC cases, **KRAS** and **GNAS** mutations were detected in the pancreatic juice of 27.3% (3/11) and 50% (2/4) of cases, respectively. Among the **KRAS** (n = 6) and **GNAS** (n = 3) mutations found in the resected pancreatic tissues of the six IPMN cases, **KRAS** and **GNAS** mutations were detected in the pancreatic juice in 66.7% (4/6) and 100% (3/3) of the cases, respectively. The percentage of cases with mutations were higher in IPMN than in PDAC; therefore, we thought that the mutations detected in the pancreatic juice could be alternative way to measure the mutations in those from tissues at least in the cases with IPMN, according to this analysis. As a result, we analysed the association between the clinical variables and **GNAS** status with the pancreatic juice in the cases with IPMN.

**Discussion**

In this study, semiconductor-based DNA sequencing was performed in clinically-obtained samples of pure pancreatic juice and resected pancreatic tissue, focusing on IPMN and IPMN-associated tumours. The analysis of the pancreatic juice revealed that the **GNAS** mutation was specific to IPMN and that the **GNAS** mutation was specifically associated with IPMN with MPD dilatation. The analysis of the resected tissues with regard to the **GNAS** mutational status demonstrated that IPMN-associated

---

**Figure 2. Genetic mutations in resected tissues.** The y-axis of the figure represents the percentage of cases with mutations in each gene. A. In the resected tissue, the **KRAS** mutation was detected in 84.6% (22 of 26 cases) of the pancreatic ductal adenocarcinoma (PDAC) cases that did not have intraductal papillary mucinous neoplasm (IPMN). B. **KRAS** and **GNAS** mutations were detected in 80% (eight of 10 cases) and 50% (five of 10 cases), respectively, of PDAC cases concomitant with IPMN. C. **KRAS** and **GNAS** mutations were detected in 66.7% (four of 6 cases) and 33.3% (two of 6 cases), respectively, of PDAC cases derived from IPMN. D. **KRAS** and **GNAS** mutations were detected in 100% (n = 6) and 66.7% (four of 6 cases), respectively, of noninvasive IPMN cases. doi:10.1371/journal.pone.0098718.g002
PDAC (both PDAC concomitant with IPMN and PDAC derived from IPMN) shared similar mutational characteristics and that these characteristics differed from those of ordinary PDAC.

Among the 46 cancer-related genes sequenced in our study, KRAS and GNAS mutations were detected with high frequency while others including TP53, SMAD4, and CDKN2A mutations were detected in only a few cases as stated before. Since there have been several previous reports that have analysed KRAS mutations in PDAC or IPMN, we focused our analysis on the GNAS mutation. Recent advances in next-generation sequencing have revealed detailed genetic alterations in cases with PDAC [6,7,9] and IPMN [12,16]. Jones et al [7], Biankin et al [9], and Wang et al [6] conducted whole-exome sequencing analysis of pancreatic PDAC and revealed that KRAS, TP53, SMAD4, and CDKN2A were the most frequently altered genes, as reported previously [8]. Of these four genes, mutations for the TP53, SMAD4, and CDKN2A genes were detected in only a few cases with PDAC in our study. Though homozygous deletion has been reported in the SMAD4 and CDKN2A genes in previous studies [8], precise identification of the homozygous deletion in clinical samples has been difficult because of DNA contamination from normal cells. However, successful detection of homozygous DNA deletion was possible for these genes in the analysis of pure pancreatic cancer cell lines (data not shown). Because only the 73 TP53 hot spot mutations from among more than 1000 mutation sites listed in the COSMIC database were targeted by the Ion AmpliSeq Cancer Primer Pools [24] and, moreover, low tumour-cellularity specimens were used, the TP53 alterations may have been underestimated in our study. These gene alterations could have been detected by other methods, such as immunohistochemistry or copy-number variation analysis. It seemed odd that some mutations as ATM, BRAF, IDH1, and RBB1 were identified in the pancreatic juice but not in the resected specimens. However, since every tissue used for the analysis was only a part of the whole tumour, it was possible that the pancreatic juice might be more representative of mutations from the entire tumour in certain conditions.

Wu et al [16] and Furukawa et al [12] performed whole-exome sequencing of IPMN from resected tissues and found that KRAS, GNAS, and RNF43 were frequently mutated genes. In this study, the KRAS and GNAS mutations were also detected in the pancreatic juice and resected tissues from the cases with IPMN. GNAS mutations have been reported in several neoplasms in the endocrine system [13,24], some pituitary adenomas [14], and in McCune–Albright syndrome [15]. GNAS mutations have also been previously reported in IPMN [11,12] cases that had pancreatic cysts [10,12,16] with a detection rate of 41–66% from resected tissues, pancreatic cyst fluids, or secretin-stimulated pancreatic juice collected from the duodenum. More recently, it has been reported that intraductal papillary neoplasms of the bile duct [25,26], pyloric gland adenoma of the stomach and duodenum [27], and low grade appendiceal mucinous neoplasms [28] resembled IPMN histologically and these neoplasms had a high frequency of GNAS mutations. GNAS encodes the α-subunit of a stimulatory G-protein (Gαs) and a mutation in GNAS causes the constitutive activation of adenyl cyclase and an elevated cAMP level [29,30]. Although the roles/functions of the GNAS mutations in IPMN or PDAC have not been elucidated, these mutations may be associated more with tumour initiation than with tumour progression because the mutation has also been observed in low-grade tumours [10,12]. In our study, GNAS mutations were detected in 41.5% of the pure pancreatic juice and in 66.7% of the resected tissue specimens from cases with IPMN; these mutation rates were nearly equal to those in previous reports. In contrast, KRAS mutations have been reported in resected tissues from both IPMN and PDAC, with respective detection rate ranges of 48–81% [12,16] and 78–100% [7,9,12], indicating that KRAS mutations can be associated with both diseases; however, the mutation rate has been somewhat higher in PDAC. The KRAS mutation detection rates in our study were equivalent to those studies of the resected tissues in both the IPMN and PDAC cases.

GNAS mutations were associated with MPD dilatation in IPMN cases through the multivariate analysis. Kanda et al reported an
Table 3. Results of univariate and multivariate analyses of GNAS status in the pancreatic juice of cases with IPMN.

|                      | Total | GNAS status | Univariate | Multivariate |
|----------------------|-------|-------------|------------|--------------|
|                      |       |             |            |              |
|                      |       | WT          | Mutation   |            | p value    | Odd's ratio (95% CI) | p value |
|                      | n     | n           | n (%)      |            |            |                      |          |
| Age                  |       |             |            |            |            |                      |          |
| ≤65                  | 24    | 14          | 10 (41.7)  | 0.981       |            |                      |          |
| >65                  | 58    | 34          | 24 (41.4)  | 0.825       |            |                      |          |
| Sex                  |       |             |            |            |            |                      |          |
| M                    | 47    | 28          | 19 (40.4)  | 0.970       |            |                      |          |
| F                    | 35    | 20          | 15 (42.9)  | 0.231       |            |                      |          |
| Location             |       |             |            |            |            |                      |          |
| Ph                   | 34    | 20          | 14 (41.2)  | 0.970       |            |                      |          |
| Pbt                  | 24    | 14          | 10 (41.7)  | 0.231       |            |                      |          |
| Tumours              |       |             |            |            |            |                      |          |
| Benign               | 45    | 29          | 16 (35.6)  | 0.048 †     | 1.181 (0.384–3.629) | 0.772 |
| Malignant            | 37    | 19          | 18 (48.6)  | 0.166       | 0.374 (0.121–1.150) | 0.086 |
| IPMN type            |       |             |            |            |            |                      |          |
| Main duct            | 33    | 15          | 18 (54.5)  | 0.048 †     | 1.181 (0.384–3.629) | 0.772 |
| Branch               | 49    | 33          | 16 (32.7)  | 0.166       | 0.374 (0.121–1.150) | 0.086 |
| Cyst size            |       |             |            |            |            |                      |          |
| ≤30 mm               | 26    | 13          | 13 (50.0)  | 0.926       |            |                      |          |
| >30 mm               | 45    | 30          | 15 (33.3)  | 0.926       |            |                      |          |
| Mural nodule         |       |             |            |            |            |                      |          |
| ≤6 mm                | 55    | 32          | 23 (41.8)  | 0.010 †     | 4.374 (1.324–14.451) | 0.016 † |
| >6 mm                | 27    | 16          | 11 (40.7)  | 0.010 †     | 4.374 (1.324–14.451) | 0.016 † |
| MPD                  |       |             |            |            |            |                      |          |
| ≥6 mm                | 26    | 10          | 16 (61.5)  | 0.010 †     | 4.374 (1.324–14.451) | 0.016 † |
| <6 mm                | 46    | 32          | 14 (30.4)  | 0.010 †     | 4.374 (1.324–14.451) | 0.016 † |
| Number of cyst       |       |             |            |            |            |                      |          |
| <3                   | 58    | 30          | 28 (48.3)  | 0.052       | 0.364 (0.105–1.266) | 0.112 |
| ≥3                   | 24    | 18          | 6 (25.0)   | 0.052       | 0.364 (0.105–1.266) | 0.112 |

WT, wild type; IPMN, intraductal papillary mucinous neoplasm; MPD, main pancreatic duct (normal MPD diameter ≤2 mm); Ph, pancreas head; Pbt, pancreas body and tail; †p < 0.05.
| Case | Age | Sex | Diagnosis | GNAS | KRAS |
|------|-----|-----|-----------|------|------|
|      |     |     |           | Mutation | VF (%) | Coverage | Mutation | VF (%) | Coverage |
| 1    | 62  | M   | WT        | G12D  | 23.0  | 634      |          |        |         |
| 2    | 73  | M   | WT        | G12R  | 16.4  | 691      |          |        |         |
| 3    | 68  | M   | WT        | G12D  | 12.2  | 809      |          |        |         |
| 4    | 63  | F   | WT        | G12V  | 6.9   | 800      |          |        |         |
| 5    | 62  | F   | WT        | G12V  | 8.8   | 2567     |          |        |         |
| 6    | 77  | M   | WT        | G12D  | 11.8  | 1441     |          |        |         |
| 7    | 51  | F   | WT        | G12D  | 12.0  | 1731     |          |        |         |
| 8    | 72  | M   | WT        | G12D  | 14.5  | 689      |          |        |         |
| 9    | 77  | F   | WT        | G12V  | 20.3  | 723      |          |        |         |
| 10   | 65  | F   | WT        | G12D  | 20.5  | 985      |          |        |         |
| 11   | 67  | M   | WT        | G12V  | 34.8  | 863      |          |        |         |
| 12   | 60  | M   | without IPMN | A146T | 1.21  | 990      |          |        |         |
| 13   | 53  | M   | WT        | G12D  | 19.24 | 2355     |          |        |         |
| 14   | 67  | M   | WT        | G12D  | 16.13 | 595      |          |        |         |
| 15   | 78  | M   | WT        | G12D  | 1.87  | 268      |          |        |         |
| 16   | 73  | F   | WT        | G12R  | 28.22 | 1244     |          |        |         |
| 17   | 57  | F   | WT        | G12R  | 55.63 | 6899     |          |        |         |
| 18   | 52  | M   | WT        | G12V  | 13.59 | 2126     |          |        |         |
| 19   | 72  | F   | WT        | G12V  | 4.92  | 488      |          |        |         |
| 20   | 71  | F   | WT        | G12V  | 32.44 | 4263     |          |        |         |
| 21   | 61  | M   | PDAC      | G12V  | 30.55 | 4458     |          |        |         |
| 22   | 78  | M   | WT        | Q61H  | 23.27 | 1985     |          |        |         |
| 23   | 78  | F   | WT        | WT    |       |          |          |        |         |
| 24   | 80  | F   | WT        | WT    |       |          |          |        |         |
| 25   | 71  | F   | WT        | WT    |       |          |          |        |         |
| 26   | 67  | M   | WT        | WT    |       |          |          |        |         |
| 27   | 82  | F   | R201C     | 5.5   | 2321  |          |          |        |         |
| 28   | 78  | M   | R201H     | 13.8  | 4075  |          |          |        |         |
| 29   | 72  | M   | R201H     | 5.7   | 2440  |          |          |        |         |
| 30   | 69  | M   | with IPMN | R201C | 1.0   | 2235     |          |        |         |
| 31   | 80  | M   | (PDAC concomitant) | R201C | 5.8   | 925      |          |        |         |
| 32   | 73  | M   | with IPMN | WT    |       |          |          |        |         |
| 33   | 78  | F   | WT        | G12V  | 25.4  | 688      |          |        |         |
| 34   | 73  | M   | WT        | G12V  | 1.9   | 1134     |          |        |         |
| Case | Age | Sex | Diagnosis          | GNAS          | KRAS          |
|------|-----|-----|--------------------|---------------|---------------|
|      |     |     |                    | Mutation      | VF (%)        | Coverage |
|      |     |     |                    |              |               |          |
| 35   | 63  | F   | WT                 | G12D          | 11.3          | 1185     |
| 36   | 79  | F   | WT                 | G12D          | 14.9          | 2563     |
| 37   | 72  | M   | R201C              | G12V          | 10.5          | 467      |
| 38   | 79  | M   | R201C              | G12D          | 16.2          | 1292     |
| 39   | 79  | F   | PDAC derived from  | Q61H          | 10.5          | 873      |
| 40   | 80  | F   | IPMN               | G12D          | 16.9          | 2330     |
| 41   | 69  | M   | WT                 |               |               |          |
| 42   | 37  | M   | WT                 |               |               |          |
| 43   | 81  | M   | R201H              | Q61H          | 48.0          | 1628     |
| 44   | 69  | M   | R201C              | G12D          | 42.9          | 815      |
| 45   | 78  | F   | IPMN without PDAC  | G12V          | 39.3          | 751      |
| 46   | 62  | M   | R201H              | G12V          | 38.3          | 650      |
| 47   | 67  | M   | R201H              | G12D          | 16.2          | 1183     |
| 48   | 76  | M   | WT                 | G12D          | 7.0           | 512      |

VF, Variant frequency; WT, wild type; PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm.

DNA from formalin-fixed, paraffin-embedded samples.

doi:10.1371/journal.pone.0098718.t004
| Case | Age | Sex | Diagnosis       | IPMN-Type | GNAS Status and IPMN | GNAS Mutation | VF (%) | KRAS Mutation | VF (%) |
|------|-----|-----|-----------------|-----------|----------------------|----------------|--------|---------------|--------|
| 1    | 73  | M   | WT              | WT        |                       | WT            |        | G12R          | 16.35  |
| 2    | 62  | F   | PDAC without    | WT        |                       | WT            |        | G12V          | 8.77   |
| 3    | 68  | M   | IPMN            | WT        |                       | WT            |        | G12D          | 12.24  |
| 4    | 62  | M   |                 | WT        |                       | WT            |        |               |        |
| 5    | 82  | F   | Branch          | R201C     |                       | 5.47           |        | G12D          | 6.45   |
| 6    | 73  | M   | Branch          | R201C     |                       | 12.77          |        | G12V          | 1.94   |
| 7    | 78  | F   | Branch          | WT        |                       |               |        | G12V          | 31.79  |
| 8    | 72  | M   | PDAC concomitant | WT        |                       |               |        | G12V          | 14.36  |
| 9    | 63  | F   | with IPMN       | WT        |                       |               |        | G12D          | 11.31  |
| 10   | 73  | M   | Branch          | WT        |                       |               |        | G12V          | 25.44  |
| 11   | 80  | F   | Branch          | WT        |                       |               |        | G12D          | 16.91  |
| 12   | 80  | M   | Branch          | R201H     |                       | 5.84           |        | WT            |        |
| 13   | 72  | M   | Main duct       | R201C     |                       | 10.38          |        | G12V          | 10.49  |
| 14   | 69  | M   | PDAC derived    | Main duct | R201C                 | 27.82          |        | G12V          | 21.62  |
| 15   | 37  | M   | Branch          | WT        |                       |               |        |               |        |
| 16   | 67  | M   | Main duct       | R201H     |                       | 10.53          |        | G12D          | 16.2   |
| 17   | 81  | M   | Main duct       | R201H     |                       | 14.39          |        | Q61H          | 17.46  |
Table 5. Cont.

| Case | Age | Sex | Diagnosis       | IPMN-Type | GNAS | Kraš | VF (%) | Mutation | VF (%) |
|------|-----|-----|-----------------|-----------|------|------|--------|----------|--------|
| 18   | 76  | M   | Main duct       | WT        | WT   | G12D | 7.03   | G12D     | 7.03   |
| 19   | 78  | F   | (Noninvasive)   | Main duct | WT   | G12V | 39.28  | G12V     | 39.28  |
| 20   | 79  | F   | Main duct       | WT        | WT   | Q61H | 10.54  | Q61H     | 10.54  |
| 21   | 62  | M   | Branch          | R201H     | R201H| G12V | 38.31  | G12V     | 38.31  |

No. of detected mutations in tissue samples: 71
No. of pancreatic juice mutations identical to tissue samples: 7
Concordance rate of mutation (%): 71.4

Upper lines of each case indicate the results for tissue samples and lower lines indicate the results for pancreatic juice.
VF, Variant frequency; WT, wild type;
PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm.

doi:10.1371/journal.pone.0098718.t005
independent association of GNAS mutations with the development of multiple cysts in cases with pancreatic cysts and Marco et al reported that IPMN with an intestinal phenotype has always been associated with GNAS mutations [10,31]. Our data confirmed the specificity of GNAS mutations to IPMN and suggested a functional role of GNAS mutations in the formation of IPMN. In particular, since MPD dilatation without obstruction in IPMN has been generally considered to be the result of mucus hypersecretion, GNAS mutations may have a role in the upregulation of mucus hypersecretion. Actually, it has been recently reported that the introduction of the GNAS mutation in cultured cells results in the upregulation of mucin genes, supporting our hypothesis [32]. A recent study reporting the high frequency of the GNAS mutation, especially in intestinal type IPMN that has conspicuous mucus production, supported our results as well [31]. Further studies of a possible causal relationship between GNAS mutations and MPD dilatation are warranted.

Similar mutation patterns of cancer-related genes were observed between the PDAC that was concomitant with IPMN and the PDAC derived from IPMN in this study. In previous studies, GNAS mutations have not been detected in ordinary PDAC with a few exceptions [12,33]. Conventionally, these tumours have been classified into three groups: ordinary PDAC, PDAC concomitant with IPMN and PDAC derived from IPMN [4,5]. A schematic classification of PDAC in terms of the relationship with IPMN is provided in Figure 4. In ordinary PDAC, no IPMN is identified in the pancreas (Fig. 4A). PDAC derived from IPMN is an invasive cancer in which a histological transition from IPMN to PDAC may be observed (Fig. 4C) [4]. On the other hand, PDAC concomitant with IPMN is a ductal adenocarcinoma that is considered to be a different disease entity from the PDAC derived from IPMN (Fig. 4D); the PDAC lesions are separate and distinct from the concomitant IPMN lesions in the pancreas on radiological imaging and histological examination. An annual incidence of an independent PDAC development of 0.8–4.1% has been reported in cases with IPMN during follow-up [5,34–36]. Although PDAC concomitant with IPMN may develop independently of IPMN, its biological behaviour resembles that of PDAC derived from IPMN because its outcome is more favourable compared with the outcomes of ordinary PDAC. Although another report studying GNAS status in PDAC concomitant with IPMN showed no mutation in six PDAC concomitant with IPMN cases, their detection sensitivity may have been lower than expected because they only detected GNAS mutations in 1 of 6 IPMN cases [37]. From the mutational pattern of GNAS observed in this study, we speculated that PDAC concomitant with IPMN and PDAC derived from IPMN may share some similar molecular mechanisms with the pathogenesis of PDAC.

Our research proved that cancer-related gene profiling by semiconductor-based sequencing is possible using small clinical samples. On the other hand, the detection sensitivity was somewhat lower in our analysis partly because of insufficient sequencing depth for each gene for a large number of genes targeted in a single analysis. Therefore, in future studies, the selection of more appropriate target genes and technical refinement of the sequence coverage may improve both sensitivity and specificity. It may be possible in the future to qualitatively diagnose tumours and to individually treat through the mutational analysis of small clinical samples such as aspirated tissues by EUS-FNA or microdissected tissues from formalin-fixed, paraffin-embedded samples.

In summary, cancer-related gene profiling was performed in this study by semiconductor-based sequencing of a small sample. The data identified in this study revealed that the GNAS mutation was specifically detected in IPMN and IPMN-associated PDAC and was associated with MPD dilatation. These findings may facilitate qualitative and quantitative diagnosis of pancreatic tumours and personalised therapy in the future.

Supporting Information

File S1 Deep-sequencing data for nine pure pancreatic juice in normal pancreas. (XLSX)

File S2 Deep-sequencing data for 22 pure pancreatic juice in chronic pancreatitis. (XLSX)

File S3 Deep-sequencing data for 39 pure pancreatic juice in pancreatic ductal adenocarcinoma (PDAC). (XLSX)

File S4 Deep-sequencing data for 82 pure pancreatic juice in intraductal papillary mucinous neoplasms (IPMN). (XLSX)

File S5 Deep-sequencing data for 26 resected tissues from PDAC without IPMN. (XLSX)

File S6 Deep-sequencing data for 10 resected tissues from PDAC concomitant with IPMN. (XLSX)
File S7 Deep-sequencing data for six resected tissues from PDAC derived from IPMN.

File S8 Deep-sequencing data for six resected tissues from IPMN.

Acknowledgments

We thank Asuka Kanayama and Takako Ohmori for their valuable technical assistance and Hiroko Amemiya and Eriko Takamuro for their secretarial assistance. The authors would like to thank Enago (www.enago.jp) for the English language review.

Author Contributions

Conceived and designed the experiments: ST NE. Performed the experiments: ST. Analyzed the data: ST SM NE. Contributed reagents/materials/analysis tools: ST MK ET. Wrote the paper: ST SM. Critical revision of the manuscript for important intellectual content: MF SM MM HS TS NE.

References

1. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, et al. (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6: 17–32.
2. Furukawa T, Kloppe G, Volkman Adsay N, Albores-Saavedra J, Fukushima N, et al. (2005) Classification of types of intraductal papillary-mucinous neoplasms of the pancreas: a consensus study. Virchows Arch A 447: 794–799.
3. Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, et al. (2012) International consensus guidelines 2012 for the management of IPMN and MGN of the pancreas. Pancreatology 12: 103–197.
4. Yamaguchi K, Kanemitsu S, Hatori T, Maguchi H, Shimizu Y, et al. (2011) Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 40: 571–580.
5. Tamo S, Nakano Y, Suyigaya Y, Nakamura K, Sasajima J, et al. (2010) Incidence and aggressiveness of intraductal pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology 10: 173–178.
6. Wang L, Tsutsumi S, Kawaguchi T, Nagasaki T, Tatsuno K, et al. (2012) GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas: a consensus study. Virchows Arch A 469: 398–802.
7. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathway alterations in pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.
8. Moore PS, Sipos B, Orlandini S, Soric C, Real FX, et al. (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch A 439: 798–802.
9. Bumak AV, Waddell N, Kasuah KS, Gingras MC, Mathuawu IA, et al. (2012) Pancreatic cancer genomes reveal alterations in axon guidance pathway genes. Nature 491: 399–405.
10. Kanda M, Knight S, Topazian M, Syngal S, Farrell J, et al. (2012) Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62: 1024–1033.
11. Wu J, Matthaei H, Mastra A, Dal Molin M, Wood LD, et al. (2011) Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 3: 92ra66.
12. Furukawa T, Kubo S, Tanji E, Yoshioka S, Hatori T, et al. (2011) Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 1: 161.
13. Stein WS, Yu S, Warner DR, Liu J (2001) Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22: 675–705.
14. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, et al. (2001) imprinting of the Gsalpha gene GNAS in the pathogenesis of acromegaly. J Clin Invest 107: R31–R36.
15. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, et al. (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325: 1680–1695.
16. Wu J, Jiao Y, Dal Molin M, Mastra A, de Wilde RF, et al. (2011) Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 108: 21186–21193.
17. Wang Y, Yamaguchi Y, Watanabe H, Ohitsuho K, Motoo Y, et al. (2004) Detection of p53 gene mutations in the supernatant of pancreatic juice and plasma from patients with pancreatic cystic lesions. Gut 53: 737–740.
18. Tateishi K, Tada M, Yamagata M, Iwayama H, Komatsuba Y, et al. (1999) High proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesions. Gut 45: 737–740.
19. Kondo H, Sugano K, Fukuyama N, Kiyosu A, Nose H, et al. (1994) Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73: 1589–1594.
20. Tada M, Onzuka M, Kawai S, Saihoo H, Ohno M, et al. (1995) Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 55: 2472–2474.
21. Kano M, Kondoh S, Okita S, Hatanos S, Shiraishi K, et al. (1999) Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors. Pancreas 18: 294–299.
22. Hossoda W, Takagi T, Mineno N, Shimizu Y, Sano T, et al. (2010) Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int 60: 358–364.
23. Beagling M, Neff TL, Heinrich MC, Rhodes K, Thornton M, et al. (2012) Combining Highly Multiplexed PCR with Semiconductor-Based Sequencing for Rapid Cancer Genotyping. J Mol Diagn 14: 171–176.
24. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nature Rev Genet 39: 945–950.
25. Sasaki M, Matsubara T, Nitza T, Sato Y, Nakamura Y (2013) GNAS and KRAS Mutations are Common in Intraductal Papillary Neoplasms of the Bile Duct. PLoS One 8: e61706.
26. Tsai JH, Yuan RH, Chen YL, Liu YY, Jeng YM (2013) GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct. Am J Surg Pathol 37: 1862–1870.
27. Matsubara A, Sekine S, Kishima R, Ogaswa R, Taniguchi H, et al. (2013) Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum. J Pathol 229: 579–587.
28. Nishikawa G, Sekine S, Ogaswa R, Matsubara A, Mori T, et al. (2013) Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 108: 951–956.
29. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, et al. (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenyl cyclase in human pituitary tumours. Nature 340: 952–954.
30. Lyons J, Landis CA, Hays JP, Allar L, Gravemekd K, et al. (1990) Two G protein oncogenes in human endocrine diseases. Science 249: 653–659.
31. Dal Molin M, Matthaei H, Wu J, Blackford A, Dephemaj M, et al. (2013) Clinico-pathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg Oncol 20: 3802–3808.
32. Komatsu H, Tanji E, Sakata N, Asaki T, Motoi F, et al. (2014) A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS One 9: e87755.
33. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, et al. (2012) Presence of somatic mutations in most early-stage pancreatic intraductal neoplasia. Gastroenterology 142: 730–739 e7339.
34. Kawakubo K, Tada M, Iwayama H, Sasahira N, Nakai Y, et al. (2013) Risk for Mortality From Causes Other Than Pancreatic Cancer in Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas 42: 687–691.
35. Uehara H, Nakaizumi A, Ishikawa O, Iishi H, Tatsumi K, et al. (2008) Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasms. Cancer Res 68: 108: 951–958.
36. Ideno N, Ohtsuka T, Kono H, Fujiwara K, Oda Y, et al. (2013) Intraductal Papillary Mucinous Neoplasms of the Pancreas With Distinct Pancreatic Ductal Adenocarcinomas Are Frequently of Gastric Subtype. Ann Surg 258: 141–151.